Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RUA Life SciencesFRA:AOHA -0.75%46 Return-on-Tangible-Asset is -4.77% as of Mar. 2026. GuruFocus rates FRA:AOHA with a GF Score™ of 46/100 and a GF Value™ of €0.15 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 853 Medical Devices & Instruments companies, RUA Life Sciences ranks worse than 56.74% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. RUA Life Sciences's annualizedNet Income for the quarter that ended in Mar. 2026 was €-0.46 Mil. RUA Life Sciences's average total tangible assets for the quarter that ended in Mar. 2026 was €9.73 Mil. Therefore, RUA Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -4.77%.
The historical rank and industry rank for RUA Life Sciences's Return-on-Tangible-Asset or its related term are showing as below:
FRA:AOHA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -74.4 Med: -32.55 Max: -2.43
Current: -2.43
During the past 13 years, RUA Life Sciences's highest Return-on-Tangible-Asset was -2.43%. The lowest was -74.40%. And the median was -32.55%.
FRA:AOHA's Return-on-Tangible-Asset is ranked worse than 56.74% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.81
vs FRA:AOHA: -2.43
RUA Life Sciences (FRA:AOHA) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
RUA Life Sciences Return-on-Tangible-Asset Related Terms
RUA Life Sciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AOHA vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, RUA Life Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -4.77% mean?
RUA Life Sciences (FRA:AOHA) has a Return-on-Tangible-Asset of -4.77% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on RUA Life Sciences and its competitors. According to the industry distribution chart, RUA Life Sciences ranks #484 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 56.7%.
Is RUA Life Sciences' Return-on-Tangible-Asset too high?
RUA Life Sciences' current Return-on-Tangible-Asset is -4.77%. Based on the distribution chart, RUA Life Sciences ranks #484 out of 853 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, RUA Life Sciences has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, RUA Life Sciences ranks #484 out of 853 companies for Return-on-Tangible-Asset. This places RUA Life Sciences in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.81, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on RUA Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RUA Life Sciences's current Return-on-Tangible-Asset is -4.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (FRA:AOHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.15, compared to a current price of €0.26 — trading 76% above its estimated fair value. The current Return-on-Tangible-Asset is -4.77%. RUA Life Sciences' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For RUA Life Sciences (FRA:AOHA), the current Return-on-Tangible-Asset is -4.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (FRA:AOHA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of €0.26 is trading 76% above its estimated GF Value™ of €0.15.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:AOHA:
Return-on-Tangible-Asset: -4.77%
GF Value™: €0.15 vs. price of €0.26 (76% above fair value)
No single metric tells the full story. See the FRA:AOHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
46GF Score
Get the complete analysis for FRA:AOHA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AOHA has been successfully added to your 
